#50 What The July FDA Hearing Could Mean For Compounded Peptides

The internet loves a scary headline, and “peptides placed in category two” might be the most misunderstood one yet. We’re Dr. Kylie Burton and Jessica Briecke, and we’re slowing the noise down to explain what’s actually happening with the FDA’s July 23–24 hearing and why it directly affects patient access to compounded peptides. It started back in 2023 when compounding pharmacies pushed back against government regulation. What happened then and what's happening now revolves around the FDA's ...